New approach to chemical biology for drug discovery: construction of new affinity beads and their application

por Handa, H
Publicado 2003

ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance

por Hashimoto, A, Hashimoto, S, Sugino, H, Yoshikawa, A, Onodera, Y, Handa, H, Oikawa, T, Sabe, H
Publicado 2016

Immortalisation of human oesophageal epithelial cells by a recombinant SV40 adenovirus vector.

por Inokuchi, S., Handa, H., Imai, T., Makuuchi, H., Kidokoro, M., Tohya, H., Aizawa, S., Shimamura, K., Ueyama, Y., Mitomi, T.
Publicado 1995

Verification of the DUCT-III for calculation of high energy neutron streaming

por Masukawa, F, Handa, H, Hayashi, K, Hirayama, H, Nakano, H, Nakashima, H, Sasamoto, N, Shin, K, Tayama, R I
Publicado 2003

PB2019: EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AND DEXAMETHASONE FOLLOWING INJECTABLE PROTEASOME INHIBITOR-BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MY...

por Sasaki, M., Suzuki, K., Abe, Y., Ito, S., Nishiwaki, K., Handa, H., Chou, T., Soeda, J., Mori, I., Shinozaki, T., Takezako, N.
Publicado 2022

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis

por Suzuki, K, Sunami, K, Ohashi, K, Iida, S, Mori, T, Handa, H, Matsue, K, Miyoshi, M, Bleickardt, E, Matsumoto, M, Taniwaki, M
Publicado 2017

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

por Ozaki, S, Handa, H, Saitoh, T, Murakami, H, Itagaki, M, Asaoku, H, Suzuki, K, Isoda, A, Matsumoto, M, Sawamura, M, Konishi, J, Sunami, K, Takezako, N, Hagiwara, S, Kuroda, Y, Chou, T, Nagura, E, Shimizu, K
Publicado 2015

Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study...

por Hayakawa, F, Sakura, T, Yujiri, T, Kondo, E, Fujimaki, K, Sasaki, O, Miyatake, J, Handa, H, Ueda, Y, Aoyama, Y, Takada, S, Tanaka, Y, Usui, N, Miyawaki, S, Suenobu, S, Horibe, K, Kiyoi, H, Ohnishi, K, Miyazaki, Y, Ohtake, S, Kobayashi, Y, Matsuo, K, Naoe, T
Publicado 2014

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

por Lopez-Girona, A, Mendy, D, Ito, T, Miller, K, Gandhi, A K, Kang, J, Karasawa, S, Carmel, G, Jackson, P, Abbasian, M, Mahmoudi, A, Cathers, B, Rychak, E, Gaidarova, S, Chen, R, Schafer, P H, Handa, H, Daniel, T O, Evans, J F, Chopra, R
Publicado 2012

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

por Lopez-Girona, A, Mendy, D, Ito, T, Miller, K, Gandhi, A K, Kang, J, Karasawa, S, Carmel, G, Jackson, P, Abbasian, M, Mahmoudi, A, Cathers, B, Rychak, E, Gaidarova, S, Chen, R, Schafer, P H, Handa, H, Daniel, T O, Evans, J F, Chopra, R
Publicado 2012